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See related research by Liu et al., http://www.ccforum.com/content/19/1/409In volume 19 (2015) of Critical Care, Liu et al. [1] present
a systematic review of risks and benefits of stress ulcer
prophylaxis (SUP) in adult neurocritical care patients. A
total of eight randomised controlled trials (RCTs) on SUP
with proton pump inhibitors or histamine-2 receptor an-
tagonists versus placebo or no prophylaxis in neurocritical
care patients was assessed. The authors conclude that SUP
is superior to placebo/no prophylaxis in reducing gastro-
intestinal (GI) bleeding and all-cause mortality, while not
increasing the risk of nosocomial pneumonia [1].
We would like to thank the authors for highlighting an
important topic with significant clinical equipoise; however,
we are worried that biased results and conclusions are pre-
sented. First, the review holds methodological limitations,
including the fact that no predefined sensitivity analysis
with continuity correction in the zero-event trials was
planned or performed, and importantly the risk of random
errors using trial sequential analysis (TSA) was not
assessed. Applying TSA to the three trials with lowest risk
of bias [1] suggests that an estimated required information
size of 2005 patients and 1790 patients are needed to* Correspondence: mortenhylander@gmail.com
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in GI bleeding and all-cause mortality, respectively. Conse-
quently, the cumulative meta-analysis presented, including
829 patients, is severely underpowered, with a high risk of
presenting spurious findings [2]. Second, all included trials
had a high risk of bias, which increases the risk of overesti-
mating the benefit and underestimating harm [3]. Third,
the authors have not assessed the potential harms of SUP
adequately, as no data were included on the important
patient-centred outcome measures of Clostridium difficile
infection and cardiovascular events [4]. Finally, applying
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) [5] to the results highlights that
the quantity and quality of evidence are low (downgraded
for risk of bias and imprecision), and that there is no firm
evidence for benefit or harm of SUP versus placebo/no
prophylaxis in adult neurocritical care patients.
In summary, adequately powered, high-quality RCTs
are needed to inform us on whether adult critically ill
patients, including those receiving neurocritical care,
benefit from routine treatment with SUP.We appreciate the attention and correspondence from
Krag et al. First, as they pointed out, TSA might be a
new promising attempt to reduce the random error risk
and to increase the information size of a cumulative
meta-analysis. We believed that the application of thisanalysis may add more statistical confidences to the
conclusion. However, the present meta-analysis was
performed in compliance with the recommendations of
the Cochrane Collaboration for intervention reviews [6].
At present, it is not compulsory to conduct TSA in adistributed under the terms of the Creative Commons Attribution 4.0
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Krag et al. Critical Care  (2016) 20:22 Page 2 of 2meta-analysis. Second, zero-cell corrections are necessary
for the Mantel–Haenszel methods if the same cell is zero
in all included studies [7], which was not the case in the
present study. Finally, and most importantly, in line with
our conclusion, Krag et al. are conservative with the
superiority of SUP versus placebo/no prophylaxis in adult
neurocritical care patients. As indicated in our meta-
analysis, the robustness of our conclusions is limited by
the lack of trials with low risk of bias, sparse data, hetero-
geneity among trials, and concern regarding small trial
bias [1]. While the present meta-analysis favoured the use
of SUP in adult neurocritical care patients based on the
preliminary evidence to date, more definitive conclusions
can only be drawn from larger, well-designed, RCTs.
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